new
   Indication of Zongertinib
501
Oct 11, 2025

Zongertinib is a novel kinase inhibitor recently granted accelerated approval by the U.S. FDA. As a targeted therapy for specific patients with non-small cell lung cancer (NSCLC), its key information—including indication, specification, physical properties, and storage method—is of great importance for clinical use.

Indication of Zongertinib

Core Indication

Zongertinib is indicated for the treatment of adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC).

The tumor must be confirmed to harbor activating mutations in the tyrosine kinase domain of HER2 (ERBB2) via an FDA-approved detection method.

The patient has previously received systemic therapy.

Usage Limitations

It is not indicated for patients without HER2 mutation testing or for those with squamous NSCLC.

Eligible patients must be screened through a companion diagnostic test (e.g., Oncomine™ Dx Target Test).

Specification and Physical Properties of Zongertinib

Specification and Physical Characteristics

Dosage Form: Oral film-coated tablets. They are oval-shaped, biconvex tablets for ease of swallowing.

Strength/Content: Each tablet contains 60 mg of zongertinib—this is the only available strength of the drug currently.

Appearance Features

Color: Yellow.

Imprint: One side is imprinted with "L6", and the other side bears the Boehringer Ingelheim company logo.

Surface Property: Film-coated with a smooth and uniform surface.

Formulation Composition

Active Ingredient: Each tablet contains 60 mg of zongertinib.

Excipients: Including colloidal silicon dioxide, croscarmellose sodium, hypromellose acetate succinate, mannitol, microcrystalline cellulose, and sodium stearyl fumarate.

Coating Ingredients: Including yellow iron oxide, glycerol monocaprylate and dicaprylate, polyvinyl alcohol, sodium lauryl sulfate, talc, and titanium dioxide.

Storage Method of Zongertinib

Temperature Control

Ideal Storage Temperature: 20°C to 25°C (68°F to 77°F).

Permitted Temporary Deviation: 15°C to 30°C (59°F to 86°F).

Packaging Features

Packaged in child-resistant bottles.

Each bottle is equipped with two silica gel desiccants to control humidity.

Commercial packaging consists of a carton containing one bottle with 60 tablets.

Other Precautions

Keep the original packaging intact and protect from moisture.

Store away from direct sunlight and heat sources.

Keep out of the reach of children.

Do not store the medication in humid environments such as bathrooms.

Note: For internal discussion among medical personnel only. For specific medication, please consult the attending physician. Drug information may change over time. For the latest information, we recommend adding a medical consultant or consulting for free online.
Zongertinib(Hernexeos)
Treatment of adult patients with advanced non-squamous non-small cell lung cancer (NSCLC) harboring HER2 TKD activating mutations following prior systemic therapy.
RELATED ARTICLES
How to Purchase Zongertinib

Zongertinib is a targeted therapeutic agent for non-small cell lung cancer (NSCLC) harboring activating mutations in...

Saturday, October 11th, 2025, 15:03
Indication of Zongertinib

Zongertinib is a novel kinase inhibitor recently granted accelerated approval by the U.S. FDA. As a targeted therapy...

Saturday, October 11th, 2025, 14:58
How to Use Zongertinib

Zongertinib is a novel kinase inhibitor indicated for the treatment of adult patients with unresectable or...

Saturday, October 11th, 2025, 14:34
Precautions for Zongertinib Administration

Zongertinib is a kinase inhibitor that targets activating mutations in the tyrosine kinase domain of HER2 (ERBB2)....

Saturday, October 11th, 2025, 14:31
RELATED MEDICATIONS
Capmatinib
Treatment of metastatic non-small cell lung cancer (NSCLC) with MET exon 14...
TOP
1
Zongertinib
Treatment of adult patients with advanced non-squamous non-small cell lung...
TOP
2
Crizotinib
Certain ALK- or ROS1-positive cancers in adults and children.
TOP
3
Dacomitinib
​A kinase inhibitor indicated for the first-line treatment of metastatic...
Cemiplimab
PD-1 inhibitor for advanced cutaneous squamous cell carcinoma, basal cell...
Adagrasib
Locally advanced or metastatic NSCLC harboring KRAS G12C mutation who have...
Contact Medical Consultant
Global Drug Search
Clinical recruitment
overseas medical treatment
Remote consultation
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Click to submit medical consultant
Contact Us
Mailbox:Info@Lucius.La
Welcome To Consult
Ucius Pharmaceuticals (Lao) Co.,Ltd All Rights Reserved